siRNA诱导CyclinB1沉默增加HePG2细胞对柔红霉素的敏感性(英文)

siRNA Induced CyclinB1 Knockdown Sensitizes HepG2 Cells to Daunorubicin

探讨了CyclinB1在肝癌药物耐受形成中的作用.用siRNA技术沉默CyclinB1在细胞中的表达,使用流式细胞仪技术分析细胞的凋亡和周期分布,用细胞克隆形成能力分析和细胞毒性实验分析细胞的增殖能力.由siRNA诱导的CyclinB1下调导致40%～50%肝癌细胞阻滞在G2/M期,并显著抑制肝癌细胞的单克隆形成能力;柔红霉素联合CyclinB1 siRNA较单独使用柔红霉素能更加有效地导致肝癌细胞凋亡,而在人正常肝细胞HL-7702中这种现象不明显.实验结果表明针对于CyclinB1的靶向性下调与肝癌药物的联合使用将有可能成为肝癌治疗的新策略.

The role of CyclinB 1 in conferring drug resistance in the treatment of liver cancer was investigated, siRNA delivery was used to knockdown the expression of CyclinB1, and flow cytometry analysis was employed to assess cell apoptosis and cell cycle distribution .Colony formation assay and cytotoxicity assay were used to determine cell growth ability. It was found that siRNA induced CyclinB 1 down regulation triggered cell arrest at G2/M by 40%-50% and greatly inhibited cell colony growth ability. Daunorubicin in combination with CyclinB1 siRNA induced more apoptosis than that treated with Daunorubicin alone, whereas this combinational effect decreased in HL-7702 cells, a normal human liver cancer cell line, Those data support the notion that targeting CyclinB1 down regulation combined with chemotherapeutical agents would be a promising new strategy in the treatment of liver cancer.